Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$80.69 USD

80.69
1,485,426

-0.16 (-0.20%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $80.80 +0.11 (0.14%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

BioMarin Pharmaceutical Inc. [BMRN]

Reports for Purchase

Showing records 681 - 700 ( 814 total )

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 681

06/17/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 17

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 682

06/05/2013

Company Report

Pages: 7

PEG-PAL for PKU Advances into Phase 3 Program

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 683

06/03/2013

Daily Note

Pages: 5

Preliminary Data for BMN-673 At ASCO Suggests An Attractive Emerging Clinical Profile, In Our View; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 684

06/03/2013

Daily Note

Pages: 29

June And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 685

06/02/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 686

05/30/2013

Company Report

Pages: 7

Vimizim Regulatory Status: US And Europe On Track For Potential Q1:14 Approvals; Reiterate NEUTRAL, But Increasing FV To $63 For Regulatory Progress

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 687

05/19/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 688

05/15/2013

Company Report

Pages: 7

BMN-673 Shows Initial Clinical Activity In BRCA Solid Tumors; Reiterating NEUTRAL, But Increasing FV to $62 With Inclusion Of BMN-673

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 689

05/10/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 690

05/03/2013

Industry Report

Pages: 30

Emerging Pharmaceuticals-May and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 691

04/30/2013

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 692

04/25/2013

Company Report

Pages: 9

Q1 Financials: Slight Miss on Top Line, But Solid Naglazyme Sales; 2013 Has Catalysts, But Stock Is Fairly Valued, In Our View; Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 693

04/16/2013

Company Report

Pages: 9

We See Potential For Q1 Miss Due To Transient QoQ Aldurazyme Fluctuations As Not Material; Reiterating NEUTRAL And $54 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 694

04/03/2013

Daily Note

Pages: 5

VIMIZIM and BMN-190 Pipeline Progress

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 695

04/01/2013

Industry Report

Pages: 30

Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 696

03/31/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 697

03/28/2013

Company Report

Pages: 8

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 698

03/26/2013

Company Report

Pages: 7

Model Update for Additional Exchange of Convertible Notes

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 699

03/19/2013

Company Report

Pages: 7

Positive Phase 1/2 Data for BMN-701/Pompe Sets Stage for Initiation of Phase 2/3 Trial by Year-end; Raising FV to $53, but Remain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 700

03/18/2013

Company Report

Pages: 7

Model Update for Partial Exchange of Convertible Notes; Reiterate NEUTRAL & $50 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party